KR-20260062952-A - Antiviral compounds and methods of manufacturing and using the same

Abstract

An antiviral compound, a method of using the same alone or in combination with additional agents, and a pharmaceutical composition of said compound for the treatment of a viral infection are disclosed.

Inventors

• 엔산, 디바
• 칼라, 라오 브이.
• 지젤, 더스틴 에스.

Assignees

• 길리애드 사이언시즈, 인코포레이티드

Dates

Publication Date

20260507

Application Date

20240827

Priority Date

20230831

Claims (20)

1. As a compound of Formula I or a pharmaceutically acceptable salt thereof, Chemical Formula I In the above formula, R1 is a C1-6 alkyl or C1-6 alkoxy; R2 is a C1-6 alkyl or C1-6 alkoxy; R3 is a C1-6 alkyl selectively substituted with -OCOR 3a ; R3a is a C1-6 alkyl selectively substituted with -NR4aR4b ; R 4a and R 4b are each independently H or C 1-6 alkyl compounds or pharmaceutically acceptable salts thereof.
2. In paragraph 1, a compound other than the following or a pharmaceutically acceptable salt thereof: , or .
3. In paragraph 1, R1 is a C1-6 alkyl, or -OC2H5 ; R₂ is a C 1-6 alkyl, or OC₂H₅ , and ; R3 is a C1-6 alkyl selectively substituted with -OCOR 3a ; R3a is a C1-6 alkyl selectively substituted with -NR4aR4b ; R 4a and R 4b are each independently H or C 1-6 alkyl compounds or pharmaceutically acceptable salts thereof.
4. In claim 1 or 3, R1 is a compound or a pharmaceutically acceptable salt thereof which is a C1-6 alkyl.
5. In claim 1 or 3, R1 is a compound or a pharmaceutically acceptable salt thereof which is a C1-3 alkyl.
6. In paragraph 1 or 3, R1 is a methyl, a compound, or a pharmaceutically acceptable salt thereof.
7. In paragraph 1 or 3, R 1 is a compound or a pharmaceutically acceptable salt thereof that is ethyl.
8. A compound or a pharmaceutically acceptable salt thereof, wherein R1 is -OC2H5 .
9. A compound or a pharmaceutically acceptable salt thereof, wherein R2 is a C1-6 alkyl.
10. A compound or a pharmaceutically acceptable salt thereof, wherein R2 is a C1-3 alkyl.
11. In any one of paragraphs 1, and 4 through 8, R2 is a methyl compound or a pharmaceutically acceptable salt thereof.
12. In any one of paragraphs 1 and 4 through 8, R2 is a compound or a pharmaceutically acceptable salt thereof that is ethyl.
13. A compound or a pharmaceutically acceptable salt thereof, wherein R2 is -OC2H5 in any one of paragraphs 1 and 4 through 8 .
14. A compound or a pharmaceutically acceptable salt thereof, wherein R3 is a C1-6 alkyl in any one of claims 1 to 12.
15. A compound or a pharmaceutically acceptable salt thereof, wherein R3 is -CH3 in any one of paragraphs 1 through 12 and 14.
16. A compound or a pharmaceutically acceptable salt thereof, wherein R3 is -C2H5 in any one of paragraphs 1 and 4 through 14 .
17. A compound or a pharmaceutically acceptable salt thereof, wherein R3 is -CH( CH3 ) 2 in any one of claims 1 to 14.
18. A compound or a pharmaceutically acceptable salt thereof, wherein R3 is -CH2CH ( CH3 ) 2 in any one of paragraphs 1 and 3 through 14.
19. A compound or a pharmaceutically acceptable salt thereof, wherein R3 is a C1-6 alkyl substituted with -OCOR 3a in any one of claims 1 and 3 to 13.
20. A compound or a pharmaceutically acceptable salt thereof, wherein R 4a and R 4b are each independently a C 1-6 alkyl.

Description

Antiviral compounds and methods of manufacturing and using the same Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 63/535,972 filed August 31, 2023, the entire contents of which are incorporated herein by reference for all purposes. Sequence list The present application includes a sequence list submitted as an electronic document in XML file format, the entirety of which is incorporated herein by reference. The name of the XML copy created on August 3, 2024 is 1483-WO-PCT.xml, and its size is 3,491 bytes. There is a need for compounds, pharmaceutical compositions, and methods for treating viral infections, e.g., infections of Paramyxoviridae , Pneumoviridae , Picornaviridae , Flaviviridae , Filoviridae , and Orthomyxoviruses . Embodiments of the present invention can address these and other requirements. In some embodiments, the present disclosure provides a compound of Formula I or a pharmaceutically acceptable salt thereof: Chemical Formula I In the above formula, R1 is a C1-6 alkyl or C1-6 alkoxy; R2 is a C1-6 alkyl or C1-6 alkoxy; R3 is a C1-6 alkyl selectively substituted with -OCOR 3a ; R3a is a C1-6 alkyl selectively substituted with -NR4aR4b ; R 4a and R 4b are each independently H or C 1-6 alkyl. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient is disclosed herein. Additionally, a method for treating or preventing a viral infection in a subject requiring treatment or prevention of a viral infection is disclosed herein, the method comprising the step of administering to the subject a compound disclosed herein or a pharmaceutically acceptable salt thereof. Additionally, a method for treating or preventing a viral infection in a human requiring treatment or prevention of a viral infection is disclosed herein, the method comprising the step of administering to the human a compound disclosed herein or a pharmaceutically acceptable salt thereof. The present disclosure provides a method for preparing a drug for the treatment or prevention of a viral infection in a subject requiring treatment or prevention of a viral infection, characterized by using the compound disclosed herein or a pharmaceutically acceptable salt thereof. The present disclosure provides a method for preparing a drug for the treatment or prevention of a viral infection in humans requiring treatment or prevention of a viral infection, characterized by using the compound disclosed herein or a pharmaceutically acceptable salt thereof. The present disclosure provides the use of the compound disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a drug for the treatment or prevention of a viral infection in humans requiring treatment or prevention of a viral infection. The present disclosure provides the use of the compound disclosed herein or a pharmaceutically acceptable salt thereof in the manufacture of a drug for the treatment or prevention of a viral infection in humans requiring treatment or prevention of a viral infection. I.General Overview The present disclosure generally relates to methods and compounds for treating or preventing viral infections, e.g., Paramyxoviridae, Pneumoviridae, Picornaviridae, Flaviviridae, Filoviridae, and Orthomyxovirus infections. The following description presents exemplary methods, parameters, etc. However, it should be recognized that such description is provided as an explanation of exemplary embodiments and is not intended to limit the scope of the present disclosure. II.definition The following words, phrases, and symbols used in this specification are generally intended to have the meanings set forth below, except as otherwise indicated by the context in which they are used. A dash (“-”) not between two letters or symbols is used to indicate the attachment point for a substituent. For example, -CONH₂ is attached through a carbon atom. Dashes before or after chemical groups are provided for convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in the structure indicates the attachment point of a group. Unless chemically or structurally required, the order in which chemical groups are listed or named does not indicate or imply directionality. The wavy lines on the chemical group shown below, for example ... indicates an attachment point, that is, it represents a broken connection where the device is connected to another described device. As used herein, “compounds of the present disclosure” may mean any compound of Formula I or II or a pharmaceutically acceptable salt thereof. Similarly, the phrase “compound of Formula (number)” means a compound of the said Formula and a pharmaceutically acceptable salt thereof. The prefix "C u -C v " indicates that the fol